Yuhan Corporation $000100.KS
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| NTCB02-1 NCT06625957 |
P3 | Recruiting | Parenteral Nutrition | 60 | 2025-07-18 |
| YH32364 NCT06975410 |
P1/2 | Recruiting | EGFR Overexpression; Locally Advanced Solid Tumor | 80 | 2027-06 |
| CLEAR NCT07415551 |
P2 | Recruiting | Allergic Diseases; Chronic Spontaneous Urticaria (CSU) | 150 | 2027-06-19 |
| YH42946 NCT06616766 |
P1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer); Solid Tumor | 201 | 2028-03-15 |
| YH32367 NCT05523947 |
P1/2 | Recruiting | HER2-Positive Solid Tumor | 147 | 2028-03-31 (+50 mo) |